To sum things up, the most significant targets—the key ligands for alleviation of the comorbidity of RA and OP—were IL-6 (PDB ID: 4NI9) and MD2-TLR4-IN-1 (PubChem ID: 138454798), respectively. This evidence concerns the gene CD44 and rheumatoid arthritis.